Opioids and brain imaging
Abstract
Keywords
Full Text:
PDFReferences
Melzack R, Casey KL: Sensory, motivational and central control determinants of pain. In Kenshalo DR (ed.): The Skin Senses. Springfield: Thomas, 1968.
Weisenberg M, Schwarzwald J, Tepper I: The influence of warning signal timing and cognitive preparation on the aversiveness of cold-pressor pain. Pain. 1996; 64: 379-385.
Petrovic P, Ingvar M: Imaging cognitive modulation of pain processing. Pain. 2002; 95: 1-5.
Sprenger T, Berthele A, Platzer S, et al.: What to learn from in vivo opioidergic brain imaging? Eur J Pain. 2005; 9(2): 117-121.
Frost JJ, Wagner HN Jr, Dannals RF, et al.: Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomogr. 1985; 9(2): 231-236.
Talbot JD, Marrett S, Evans AC, et al.: Multiple representations of pain in human cerebral cortex. Science. 1991; 251: 1355-1358.
Chen AC: New perspectives in EEG/MEG brain mapping and PET/fMRI neuroimaging of human pain. Int J Psychophysiol. 2001; 42(2): 147-159.
Davis KD, Wood ML, Crawley AP, et al.: fMRI of human somatosensory and cingulate cortex during painful electrical nerve stimulation. Neuroreport. 1995; 7(1): 321-325.
Davis KD, Kwan CL, Crawley AP, et al.: Event-related fMRI of pain: Entering a new era in imaging pain. Neuroreport. 1998; 9(13): 3019-3023.
Lingford-Hughes A: Human brain imaging and substance abuse. Curr Opin Pharmacol. 2005; 5: 42-46.
Tracey I: Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J Clin Pharmacol. 2001; 41: 21S-28S.
Newberg AB, Wang J, Rao H: Concurrent CBF and CMRG1c changes during human brain activation by combined fMRI-PET scanning. Neuroimage. 2005; 28: 500-506.
Schulthess GK: Positron emission tomography versus positron emission tomography/computed tomography: From “unclear” to “new-clear” medicine. Mol Imaging Biol. 2004; 6(4): 183-187.
Beyer T, Antoch G, Müller S, et al.: Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004; 45: 25S-35S.
Vogel WV, Oyen WJG, Barentsz JO, et al.: PET/CT: Panacea, redundancy, or something in between? J Nucl Med. 2004; 45: 15S-24S.
Pichler BJ, Judenhofer MS, Catana C, et al.: Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med. 2006; 47(4): 639-647.
Frost JJ: PET imaging of the opioid receptor: The early years. Nucl Med Biol. 2001; 28(5): 509-513.
Dannals RF, Ravert HT, Frost JJ, et al.: Radiosynthesis of an opiate receptor binding radiotracer: [11C]carfentanil. Int J Appl Radiat Isot. 1985; 36(4): 303-306.
Henriksen G, Platzer S, Hauser A: 18F-labeled sufentanil for PET-imaging of m-opioid receptors. Bioorg Med Chem Lett. 2005; 15: 1773-1777.
Talbot PS, Narendran R, Butelman ER, et al.: 11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: Synthesis and evaluation in baboons. J Nucl Med. 2005; 46(3): 484-494.
Pert CB, Snyder SH: Opiate receptor: Demonstration in nervous tissue. Science. 1973; 179(77): 1011-1014.
Bencherif B, Fuchs PN, Sheth R, et al.: Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET). Pain. 2002; 99(3): 589-598.
Peyron R, Laurent B, Garcia-Larrea L: Functional imaging of brain responses to pain. A review and meta-analysis. Neurophysiol Clin. 2000; 30(5): 263-288.
Albe-Fessard D, Berkley KJ, Kruger L, et al.: Diencephalic mechanisms of pain sensation. Brain Res. 1985; 356(3): 217-296.
Zubieta JK, Dannals RF, Frost JJ: Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry. 1999; 156(6): 842-848.
Schadrack J, Willoch F, Platzer S, et al.: Opioid receptors in the human cerebellum: Evidence from [11C]diprenorphine PET, mRNA expression and autoradiography. Neuroreport. 1999; 10(3): 619-624.
Adler LJ, Gyulai FE, Diehl DJ: Regional brain activity changes associated with fentanyl analgesia elucidated by positron emission tomography. Anesth Analg. 1997; 84: 120-126.
Corbetta M, Miezin FM, Dobmeyer S, et al.: Selective and divided attention during visual discriminations of shape, color, and speed: Functional anatomy by positron emission tomography. J Neurosci. 1991; 11(8): 2383-2402.
Sprenger T, Wagner K, Willoch F, et al.: Hot-spots of opioid receptor activation by m-agonists—a fusion study of [11C]-diprenorphine and H215O-PET. J Cereb Blood Flow Metab. 2003; 23(suppl. 1): 715.
Wise RG, Williams P, Tracey I: Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain. Neuropsychopharmacology. 2004; 29(3): 626-635.
Grevert P, Albert LH, Goldstein A: Partial antagonism of placebo analgesia by naloxone. Pain. 1983; 16(2): 129-143.
Borras MC, Becerra L, Ploghaus A, et al.: FMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. J Neurophysiol. 2004; 91: 2723-2733.
Petrovic P, Kalso E, Petersson KM, et al.: Placebo and opioid analgesia—imaging a shared neuronal network. Science.2002; 295: 1737-1740.
Amanzio M, Benedetti F: Neuropharmacological dissection of placebo analgesia: Expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999; 19(1): 484-494.
Wager TD, Rilling JK, Smith EE, et al.: Placebo-induced changes in FMRI in the anticipation and experience of pain. Science. 2004; 303(5661): 1162-1167.
Zubieta JK, Bueller JA, Jackson LR, et al.: Placebo effects mediated by endogenous opioid activity on m-opioid receptors. J Neurosci. 2005; 25(34): 7754-7762.
Zubieta JK, Smith YR, Bueller JA, et al.: Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science. 2001; 293(5528): 311-315.
Willoch F, Tolle TR, Wester HJ, et al.: Central pain after pontine infarction is associated with changes in opioid receptor binding: A PET study with 11C-diprenorphine. AJNR Am J Neuroradiol. 1999; 20(4): 686-690.
Jones AK, Watabe H, Cunningham VJ, et al.: Cerebral decreases in opioid receptor binding in patients with central neuropathic pain measured by [11C]diprenorphine binding and PET. Eur J Pain. 2004; 8(5): 479-485.
Roache JD: Performance and physiological measures in abuse liability evaluation. Br J Addict. 1991; 86(12): 1595-1600.
Zubieta JK, Gorelick DA, Stauffer R, et al.: Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med. 1996; 2(11): 1225-1229.
Machulla HJ, Heinz A: Radioligands for brain imaging of the kappa-opioid system. J Nucl Med. 2005; 46(3): 386-387.
Kling MA, Carson RE, Borg L, et al.: Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000; 295(3): 1070-1076.
Melichar JK, Hume SP, Williams TM, et al.: Using [11C]-Diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: Clinical and preclinical studies. J Pharmacol Exp Ther. 2005; 312(1): 309-315.
Greenwald MK, Johanson CE, Moody DE, et al.: Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in hero-in-dependent volunteers. Neuropsychopharmacology. 2003; 28: 2000-2009.
Xu X, Fukuyama H, Yazawa S, et al.: Functional localization of pain perception in the human brain studied by PET. Neuroreport. 1997; 8(2): 555-559.
Porro CA: Functional imaging and pain: Behavior, perception, and modulation. Neuroscientist. 2003; 9(5): 354-369.
Bucher SF, Seelos KC, Oertel WH, et al.: Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol. 1997; 41(5): 639-645.
DOI: https://doi.org/10.5055/jom.2006.0024
Refbacks
- There are currently no refbacks.